Welcome to our dedicated page for Cumberland Pharmaceuticals news (Ticker: CPIX), a resource for investors and traders seeking the latest updates and insights on Cumberland Pharmaceuticals stock.
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) is a specialty pharmaceutical company whose news flow centers on its portfolio of FDA-approved brands and its clinical development programs. The company focuses on hospital acute care, gastroenterology, and oncology markets, and its announcements often highlight product milestones, commercialization agreements, and study results that affect how its medicines are used in practice.
Recent news has covered developments for Caldolor (ibuprofen) injection, including a permanent CMS J-code associated with a reimbursement price that supports its use as a non-opioid option for managing pain and fever. Cumberland has also reported regulatory approval of its ibuprofen injection product in Mexico through a partnership with PiSA Farmaceutica, reflecting the company’s efforts to expand access to its hospital acute care therapies internationally.
Another recurring theme in CPIX news is the expansion of Vibativ (telavancin) injection. Press releases describe new supply arrangements and group purchasing agreements with organizations such as Vizient and Premier in the United States, as well as the launch of Vibativ in Saudi Arabia through Tabuk Pharmaceutical Manufacturing Company. These updates explain how hospitals and providers can access Vibativ in different configurations and markets.
Cumberland’s news also highlights its ifetroban Phase II clinical programs in Duchenne Muscular Dystrophy cardiomyopathy, Systemic Sclerosis, and Idiopathic Pulmonary Fibrosis, including presentations of trial data and regulatory interactions. In addition, investors can follow revenue updates and quarterly financial results, which break down net revenues by product such as Kristalose, Sancuso, Vibativ, and Caldolor.
For readers tracking CPIX, the news stream provides insight into product-level performance, international partnerships, reimbursement developments, and the progress of late-stage clinical studies. Bookmarking this page can help investors, clinicians, and other stakeholders follow key events affecting Cumberland’s commercial portfolio and pipeline.
Cumberland Pharmaceuticals (Nasdaq: CPIX) announced on Dec 8, 2025 that Caldolor® (ibuprofen) Injection's permanent J-code J1741 is now officially associated with a reimbursement price, creating a CMS-covered, non-opioid option for pain and fever management.
The update links an established reimbursement price to J1741, which the company says supports opioid-sparing strategies, encourages providers to update billing systems, and may improve access to Caldolor for adult and pediatric patients where ibuprofen is indicated.
Cumberland Pharmaceuticals (Nasdaq: CPIX) reported third-quarter 2025 net revenues of $8.3 million and year-to-date net revenues of $30.8 million, a 12% increase versus the first nine months of 2024. The company ended the quarter with approximately $66 million in total assets, $40 million in liabilities and $26 million of shareholders' equity, including $15 million in cash.
Recent developments include a co-commercialization and 30% ownership stake in newly formed Talicia Holdings (Talicia), international launches and approvals for Vibativ and an ibuprofen injection, inclusion of Vibativ in Vizient and Premier purchasing arrangements, and ongoing Phase II ifetroban programs with positive FIGHT DMD findings submitted to the FDA.
Cumberland Pharmaceuticals (Nasdaq: CPIX) will release its third quarter 2025 financial results and provide a company update after market close on Tuesday, Nov. 4, 2025. A conference call to discuss results is scheduled for Nov. 4 at 4:30 p.m. ET. Participants must register online to receive dial‑in/PIN details or use a "Call Me" option. A replay will be available for one year via the company's Investor Relations page or the provided media-server link.
The company is a specialty pharmaceutical firm with FDA‑approved hospital and oncology products including Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ, and is running Phase II trials of ifetroban in systemic sclerosis, DMD cardiomyopathy, and idiopathic pulmonary fibrosis. For full prescribing information and product links visit the company website.
Cumberland (Nasdaq: CPIX) announced a co-commercialization joint venture with RedHill (Nasdaq: RDHL) to jointly commercialize the FDA-approved H. pylori therapy Talicia effective Oct 20, 2025.
Key terms: Cumberland will invest $4.0M, assume U.S. distribution and record sales; Talicia net revenues were $8.0M in 2024; net revenues will be shared 50/50. Product protections include U.S. patents through 2042 and 8 years QIDP exclusivity. Broad coverage and retail access include ~70% commercial and 60% government coverage and stocking at 1,700 CVS pharmacies.
RedHill (NASDAQ: RDHL) announced a strategic partnership with Cumberland Pharmaceuticals (NASDAQ: CPIX) on Oct 20, 2025 in which Cumberland will invest $4.0 million for a 30% ownership stake and joint control of RedHill's Talicia business, with RedHill retaining 70%.
The companies agreed an equal-sharing U.S. co-commercialization deal for Talicia's net revenues, with Cumberland providing national sales, marketing and operational support. Talicia is patent protected through 2042 and holds eight years of U.S. QIDP exclusivity. The transaction also contributes to RedHill's belief that it has stockholders' equity above the $2.5 million Nasdaq continued-listing threshold as of the press release date.
Cumberland Pharmaceuticals (NASDAQ:CPIX) announced that its antibiotic Vibativ (telavancin) was added to a national group purchasing agreement with Premier, Inc., effective October 1, 2025.
Premier membership includes about 4,350 U.S. hospitals and 325,000 other providers; the agreement makes Premier’s pre‑negotiated pricing and terms available to members for Vibativ in both the existing 12‑vial carton and a newly introduced 4‑vial Starter Pak, intended to support inpatient and outpatient ordering flexibility and inventory management.
Cumberland Pharmaceuticals (NASDAQ: CPIX) has received regulatory approval for its injectable ibuprofen product in Mexico through a partnership with PiSA Farmaceutica. The product, designed for pain management and fever reduction in hospital and surgical settings, will be supplied in 800 mg vials.
Under the partnership agreement, Cumberland provides regulatory and manufacturing support, while PiSA led the regulatory process and will handle the product launch in Mexico. The injectable ibuprofen has demonstrated significant benefits in reducing post-operative pain and decreasing opioid medication requirements, supporting multimodal, opioid-sparing pain management strategies.
Cumberland Pharmaceuticals (NASDAQ:CPIX) and Tabuk Pharmaceutical Manufacturing Company have launched Vibativ® (telavancin) injection in Saudi Arabia. This FDA-approved antibiotic is designed to treat hospital-acquired and ventilator-associated pneumonia, including infections from flu and COVID-19, as well as serious skin infections.
The drug specifically targets drug-resistant bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA) and Methicillin-sensitive Staphylococcus aureus (MSSA). Vibativ maintains its potency against difficult-to-treat bacteria even after 10 years since introduction, featuring a unique molecular design that combines lipophilic and hydrophilic components to enhance cell wall penetration and tissue reach.
The launch follows an exclusive agreement granting Tabuk rights to register and promote Vibativ in Saudi Arabia and other Middle Eastern countries.
Cumberland Pharmaceuticals (NASDAQ:CPIX) reported strong financial performance with Q2 2025 revenues of $10.8 million, up 10% year-over-year, and year-to-date revenues of $22.6 million, representing a 23% increase. The company's key developments include the launch of Vibativ® 4-Vial Starter Pak through Vizient Inc., and breakthrough findings from the Phase II FIGHT DMD trial showing 5.4% improvement in cardiac function with ifetroban.
Q2 2025 product revenues included $2.8M for Kristalose®, $3.1M for Sancuso®, $2.7M for Vibativ®, and $1.6M for Caldolor®. The company reported a Q2 net loss of $741,000 but maintained year-to-date net income of $516,000. Cumberland ended Q2 with $68M in total assets, including $16M in cash, and $28M in shareholders' equity.
Cumberland Pharmaceuticals (NASDAQ: CPIX) has secured a significant contract with Vizient, the nation's largest healthcare performance improvement company, for its new Vibativ® 4-Vial Starter Pak. Vizient serves over 65% of U.S. acute care providers, including 97% of academic medical centers.
Vibativ® is an FDA-approved injectable antibiotic for treating hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) and complicated skin infections caused by Gram-positive pathogens, including MRSA. The drug has demonstrated significantly higher cure rates compared to vancomycin in HABP/VABP cases with specific pathogen profiles.
This contract enhances accessibility to Vibativ's new 4-vial configuration, supporting flexible treatment initiation across inpatient and outpatient settings.
FAQ
What is the current stock price of Cumberland Pharmaceuticals (CPIX)?
What is the market cap of Cumberland Pharmaceuticals (CPIX)?
